Insider Trading activities of Neurocrine Biosciences Inc insiders. , Part 2

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Neurocrine Biosciences Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Neurocrine Biosciences Inc since year 2005. (See page 1 of this report.) Table 2 shows the detailed insider transactions of Neurocrine Biosciences Inc since 2005. The reporting company's ticker symbol is NBIX. The reporting company's CIK number is 914475.
The total value of stock buying since 2005 is $10,350,601.
The total value of stock sales since 2005 is $101,285,623.
The total value of stock option exercises since 2005 is $11,415,605.


 1   2 

Table 2. Detailed insider stock purchases, sales, and option exercises of Neurocrine Biosciences Inc insiders (NBIX) , Part 2
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2015-04-07 Sherwin Stephen A (Director) Option Ex 15,000 4.76 71,400
2015-04-07 Neurocrine Biosciences Inc (Director) Option Ex 15,000 4.76 71,400
2015-03-24 Gorman Kevin Charles (President and CEO) Sale 40,000 41.53 1,661,200
2015-03-24 Gorman Kevin Charles (President and CEO) Option Ex 40,000 2.59 103,600
2015-03-24 Lyons Gary A (Director) Sale 30,000 41.53 1,245,900
2015-03-20 Coughlin Timothy P (Chief Financial Officer) Sale 40,000 44.49 1,779,600
2015-03-20 Coughlin Timothy P (Chief Financial Officer) Option Ex 40,000 2.59 103,600
2015-02-23 Grigoriadis Dimitri E. (Chief Research Officer) Sale 20,000 40.00 800,000
2015-02-23 Grigoriadis Dimitri E. (Chief Research Officer) Option Ex 20,000 5.76 115,200
2015-02-10 Grigoriadis Dimitri E. (Chief Research Officer) Sale 20,000 35.00 700,000
2015-02-10 Grigoriadis Dimitri E. (Chief Research Officer) Option Ex 20,000 5.76 115,200
2015-02-10 Lyons Gary A (Director) Option Ex 7,500 4.76 35,700
2015-01-20 Lyons Gary A (Director) Option Ex 7,500 4.76 35,700
2015-01-16 Gano Kyle (Chief Business Dev Officer) Sale 1,625 30.80 50,050
2015-01-16 Grigoriadis Dimitri E. (Chief Research Officer) Sale 1,625 30.77 50,001
2015-01-16 Bozigian Haig P. (Chief Development Officer) Sale 1,625 30.79 50,033
2015-01-16 Coughlin Timothy P (Chief Financial Officer) Sale 1,750 30.81 53,917
2015-01-16 Obrien Christopher Flint (Chief Medical Officer) Sale 1,750 30.79 53,882
2015-01-16 Gorman Kevin Charles (President and CEO) Sale 3,750 30.79 115,462
2015-01-13 Gano Kyle (Chief Business Dev Officer) Sale 25,000 30.00 750,000
2015-01-13 Gano Kyle (Chief Business Dev Officer) Option Ex 25,000 4.17 104,375
2015-01-13 Grigoriadis Dimitri E. (Chief Research Officer) Sale 20,000 30.00 600,000
2015-01-13 Grigoriadis Dimitri E. (Chief Research Officer) Option Ex 20,000 5.76 115,200
2015-01-13 Mitchell W Thomas (Director) Sale 45,000 30.07 1,353,150
2015-01-13 Mitchell W Thomas (Director) Option Ex 45,000 4.51 202,814
2015-01-12 Gano Kyle (Chief Business Dev Officer) Sale 1,250 28.41 35,512
2015-01-12 Grigoriadis Dimitri E. (Chief Research Officer) Sale 1,625 28.38 46,117
2015-01-12 Bozigian Haig P. (Chief Development Officer) Sale 1,625 28.45 46,231
2015-01-12 Coughlin Timothy P (Chief Financial Officer) Sale 1,750 28.37 49,647
2015-01-12 Obrien Christopher Flint (Chief Medical Officer) Sale 1,750 28.41 49,717
2015-01-12 Gorman Kevin Charles (President and CEO) Sale 3,750 28.43 106,612
2015-01-08 Grigoriadis Dimitri E. (Chief Research Officer) Sale 30,000 27.39 821,700
2015-01-08 Grigoriadis Dimitri E. (Chief Research Officer) Option Ex 30,000 2.59 77,700
2015-01-08 Bozigian Haig P. (Chief Development Officer) Sale 30,000 27.30 819,150
2015-01-08 Bozigian Haig P. (Chief Development Officer) Option Ex 30,000 2.59 77,700
2015-01-08 Coughlin Timothy P (Chief Financial Officer) Sale 10,000 27.25 272,500
2015-01-08 Coughlin Timothy P (Chief Financial Officer) Option Ex 10,000 2.59 25,900
2015-01-08 Obrien Christopher Flint (Chief Medical Officer) Sale 55,000 27.24 1,498,200
2015-01-08 Obrien Christopher Flint (Chief Medical Officer) Option Ex 55,000 2.59 142,450
2015-01-08 Gorman Kevin Charles (President and CEO) Sale 25,000 27.39 684,750
2015-01-08 Gorman Kevin Charles (President and CEO) Option Ex 25,000 2.59 64,750
2015-01-05 Grigoriadis Dimitri E. (Chief Research Officer) Sale 2,500 22.76 56,900
2015-01-05 Grigoriadis Dimitri E. (Chief Research Officer) Option Ex 2,500 5.12 12,800
2015-01-05 Bozigian Haig P. (Chief Development Officer) Sale 2,500 22.76 56,900
2015-01-05 Bozigian Haig P. (Chief Development Officer) Option Ex 2,500 5.12 12,800
2015-01-02 Mitchell W Thomas (Director) Sale 8,000 22.79 182,320
2015-01-02 Mitchell W Thomas (Director) Option Ex 8,000 4.76 38,080
2014-12-19 Coughlin Timothy P (Chief Financial Officer) Sale 10,000 24.02 240,200
2014-12-19 Coughlin Timothy P (Chief Financial Officer) Option Ex 10,000 2.59 25,900
2014-12-19 Obrien Christopher Flint (CHIEF MEDICAL OFFICER) Sale 20,000 24.02 480,400
2014-12-19 Obrien Christopher Flint (CHIEF MEDICAL OFFICER) Option Ex 20,000 2.59 51,800
2014-12-19 Gorman Kevin Charles (PRESIDENT AND CEO) Sale 15,000 24.01 360,150
2014-12-18 Coughlin Timothy P (Chief Financial Officer) Sale 20,000 23.18 463,600
2014-12-18 Coughlin Timothy P (Chief Financial Officer) Option Ex 20,000 2.59 51,800
2014-12-18 Gorman Kevin Charles (PRESIDENT AND CEO) Sale 55,000 23.24 1,278,200
2014-12-18 Gorman Kevin Charles (PRESIDENT AND CEO) Option Ex 70,000 4.28 299,390
2014-12-17 Gano Kyle (Chief Business Dev Officer) Sale 4,957 22.50 111,532
2014-12-17 Gano Kyle (Chief Business Dev Officer) Option Ex 4,957 5.00 24,785
2014-12-17 Grigoriadis Dimitri E. (Chief Research Officer) Sale 14,706 22.50 330,885
2014-12-17 Grigoriadis Dimitri E. (Chief Research Officer) Option Ex 14,706 2.59 38,088
2014-12-17 Bozigian Haig P. (Chief Development Officer) Sale 15,002 22.51 337,695
2014-12-17 Bozigian Haig P. (Chief Development Officer) Option Ex 15,002 2.59 38,855
2014-12-15 Grigoriadis Dimitri E. (Chief Research Officer) Sale 2,500 21.71 54,275
2014-12-15 Grigoriadis Dimitri E. (Chief Research Officer) Option Ex 2,500 5.12 12,800
2014-12-15 Bozigian Haig P. (Chief Development Officer) Sale 2,500 21.72 54,300
2014-12-15 Bozigian Haig P. (Chief Development Officer) Option Ex 2,500 5.12 12,800
2014-12-12 Gano Kyle (Chief Business Dev Officer) Sale 4,043 22.50 90,967
2014-12-12 Gano Kyle (Chief Business Dev Officer) Option Ex 4,043 5.00 20,215
2014-12-12 Grigoriadis Dimitri E. (Chief Research Officer) Sale 10,294 22.50 231,615
2014-12-12 Grigoriadis Dimitri E. (Chief Research Officer) Option Ex 10,294 3.85 39,683
2014-12-12 Bozigian Haig P. (Chief Development Officer) Sale 9,998 22.50 224,955
2014-12-12 Bozigian Haig P. (Chief Development Officer) Option Ex 9,998 3.85 38,542
2014-12-12 Mollica Joseph A (Director) Option Ex 20,000 4.76 95,200
2014-12-11 Obrien Christopher Flint (Chief Medical Officer) Sale 19,875 22.10 439,237
2014-12-11 Obrien Christopher Flint (Chief Medical Officer) Option Ex 19,875 2.59 51,476
2014-12-10 Coughlin Timothy P (Chief Financial Officer) Sale 20,000 21.48 429,500
2014-12-10 Coughlin Timothy P (Chief Financial Officer) Option Ex 20,000 3.85 77,100
2014-12-10 Obrien Christopher Flint (Chief Medical Officer) Sale 20,125 21.77 438,221
2014-12-10 Obrien Christopher Flint (Chief Medical Officer) Option Ex 20,125 2.59 52,123
2014-12-10 Mitchell W Thomas (Director) Sale 7,000 21.90 153,300
2014-12-10 Mitchell W Thomas (Director) Option Ex 7,000 4.76 33,320
2014-11-28 Coughlin Timothy P (Chief Financial Officer) Sale 10,000 20.14 201,400
2014-11-24 Obrien Christopher Flint (Chief Medical Officer) Sale 5,463 19.53 106,692
2014-11-17 Obrien Christopher Flint (Chief Medical Officer) Sale 11,300 19.51 220,463
2014-11-13 Obrien Christopher Flint (Chief Medical Officer) Sale 3,237 19.50 63,121
2014-11-10 Obrien Christopher Flint (Chief Medical Officer) Sale 20,000 18.62 372,400
2014-10-31 Coughlin Timothy P (Chief Financial Officer) Sale 10,000 19.00 190,000
2014-10-30 Coughlin Timothy P (Chief Financial Officer) Sale 10,000 18.62 186,200
2014-10-28 Coughlin Timothy P (Chief Financial Officer) Sale 10,000 18.00 180,000
2014-10-01 Mitchell W Thomas (Director) Sale 1,275 15.50 19,762
2014-09-15 Lyons Gary A (Director) Sale 20,000 15.66 313,200
2014-05-12 Nevinny Corinne H (Director) Option Ex 12,000 12.37 148,440
2014-05-12 Pops Richard F (Director) Option Ex 12,000 12.37 148,440
2014-04-16 Mitchell W Thomas (Director) Option Ex 12,000 12.37 148,440
2014-04-16 Mollica Joseph A (Director) Option Ex 15,000 12.37 185,550
2014-04-16 Sherwin Stephen A (Director) Option Ex 12,000 12.37 148,440
2014-03-07 Lyons Gary A (Director) Option Ex 85,000 10.98 933,300
2014-01-17 Grigoriadis Dimitri E. (CHIEF RESEARCH OFFICER) Sale 25,000 20.00 500,000
2014-01-17 Grigoriadis Dimitri E. (CHIEF RESEARCH OFFICER) Option Ex 25,000 3.85 96,375
2014-01-17 Bozigian Haig P. (CHIEF DEVELOPMENT OFFICER) Sale 25,000 20.00 500,000
2014-01-17 Bozigian Haig P. (CHIEF DEVELOPMENT OFFICER) Option Ex 25,000 3.85 96,375
2014-01-10 Gano Kyle (Chief Business Dev Officer) Sale 1,250 18.57 23,212
2014-01-10 Grigoriadis Dimitri E. (Chief Research Officer) Sale 1,625 18.56 30,159
2014-01-10 Bozigian Haig P. (Chief Development Officer) Sale 1,625 18.58 30,192
2014-01-10 Coughlin Timothy P (Chief Financial Officer) Sale 1,750 18.56 32,479
2014-01-10 Obrien Christopher Flint (Chief Medical Officer) Sale 6,750 18.77 126,731
2014-01-10 Gorman Kevin Charles (President and CEO) Sale 3,750 18.57 69,637
2014-01-07 Grigoriadis Dimitri E. (Chief Research Officer) Sale 25,000 17.50 437,500
2014-01-07 Bozigian Haig P. (Chief Development Officer) Sale 25,000 17.50 437,500
2014-01-07 Coughlin Timothy P (Chief Financial Officer) Sale 70,000 16.75 1,172,500
2014-01-07 Obrien Christopher Flint (Chief Medical Officer) Sale 5,000 17.50 87,500
2014-01-07 Gorman Kevin Charles (President and CEO) Sale 108,000 16.76 1,810,080
2013-09-04 Gano Kyle (Chief Business Dev Officer) Sale 2,400 15.61 37,464
2013-09-03 Obrien Christopher Flint (Chief Medical Officer) Sale 5,000 16.00 80,000
2013-08-21 Grigoriadis Dimitri E. (Chief Research Officer) Sale 13,600 15.04 204,612
2013-08-21 Bozigian Haig P. (Chief Development Officer) Sale 13,999 15.04 210,544
2013-08-21 Coughlin Timothy P (Chief Financial Officer) Sale 19,035 15.05 286,476
2013-08-06 Mitchell W Thomas (Director) Sale 1,531 14.70 22,505
2013-08-05 Grigoriadis Dimitri E. (Chief Research Officer) Sale 11,400 15.01 171,057
2013-08-05 Bozigian Haig P. (Chief Development Officer) Sale 11,001 15.00 165,015
2013-08-05 Coughlin Timothy P (Chief Financial Officer) Sale 10,965 14.99 164,365
2013-08-05 Obrien Christopher Flint (Chief Medical Officer) Sale 5,000 15.00 75,000
2013-07-12 Obrien Christopher Flint (Chief Medical Officer) Sale 5,000 14.50 72,500
2013-06-28 Obrien Christopher Flint (Chief Medical Officer) Sale 7,500 13.50 101,250
2013-06-27 Grigoriadis Dimitri E. (Chief Research Officer) Sale 3,837 13.00 49,881
2013-06-27 Bozigian Haig P. (Chief Development Officer) Sale 8,000 13.00 104,000
2013-06-27 Obrien Christopher Flint (Chief Medical Officer) Sale 3,857 13.00 50,141
2013-06-24 Bozigian Haig P. (Chief Development Officer) Sale 769 12.72 9,781
2013-06-21 Grigoriadis Dimitri E. (Chief Research Officer) Sale 25,937 12.80 331,915
2013-06-21 Bozigian Haig P. (Chief Development Officer) Sale 23,962 12.73 304,964
2013-06-21 Obrien Christopher Flint (Chief Medical Officer) Sale 14,926 12.70 189,515
2013-06-20 Grigoriadis Dimitri E. (Chief Research Officer) Sale 20,900 12.41 259,473
2013-06-20 Bozigian Haig P. (Chief Development Officer) Sale 20,769 12.43 258,054
2013-06-20 Obrien Christopher Flint (Chief Medical Officer) Sale 21,217 12.39 262,984
2013-03-28 Mitchell W Thomas (Director) Option Ex 12,000 10.60 127,200
2013-03-28 Nevinny Corinne H (Director) Option Ex 12,000 10.60 127,200
2013-03-28 Pops Richard F (Director) Option Ex 12,000 10.60 127,200
2013-03-28 Mollica Joseph A (Director) Option Ex 15,000 10.60 159,000
2013-03-28 Sherwin Stephen A (Director) Option Ex 12,000 10.60 127,200
2012-12-05 Mitchell W Thomas (Director) Sale 900 7.41 6,669
2011-10-12 Lampert Mark N (10% Owner) Buy 29,500 5.96 175,672
2011-10-11 Lampert Mark N Buy 3,800 5.73 21,770
2011-10-10 Lampert Mark N Buy 70,100 5.59 391,718
2011-02-28 Grigoriadis Dimitri E. (Vice President, Research) Sale 12,320 6.82 84,071
2011-02-28 Bozigian Haig P. (Sr Vice President, Development) Sale 12,320 6.83 84,084
2011-02-28 Coughlin Timothy P (VP and Chief Financial Officer) Sale 12,320 6.83 84,108
2011-02-28 Obrien Christopher Flint (Sr. VP & Chief Medical Officer) Sale 12,320 6.83 84,096
2011-02-28 Gorman Kevin Charles (President and CEO) Sale 15,400 6.83 105,135
2011-02-28 Valeur Jensen Margaret E (EVP and General Counsel) Sale 12,320 6.83 84,108
2010-04-12 Bvf Inc/il (10% Owner) Sale 104,000 2.80 291,408
2010-04-09 Bvf Inc/il (10% Owner) Sale 94,000 2.76 259,252
2010-03-31 Bvf Inc/il (10% Owner) Sale 1,000 2.70 2,700
2010-03-30 Bvf Inc/il (10% Owner) Sale 104,000 2.70 280,800
2010-03-29 Bvf Inc/il (10% Owner) Sale 77,100 2.70 208,324
2010-03-26 Bvf Inc/il (10% Owner) Sale 31,200 2.70 84,240
2010-03-25 Bvf Inc/il (10% Owner) Sale 304,800 2.70 822,960
2010-03-24 Bvf Inc/il (10% Owner) Sale 88,000 2.75 242,352
2010-03-23 Bvf Inc/il (10% Owner) Sale 29,000 2.75 79,750
2010-03-22 Bvf Inc/il (10% Owner) Sale 72,000 2.77 199,368
2010-03-01 Grigoriadis Dimitri E. (Vice President, Research) Sale 13,955 2.53 35,320
2010-03-01 Bozigian Haig P. (Sr Vice President, Development) Sale 14,090 2.53 35,591
2010-03-01 Coughlin Timothy P (VP and Chief Financial Officer) Sale 12,650 2.53 31,966
2010-03-01 Obrien Christopher Flint (Sr. VP & Chief Medical Officer) Sale 13,490 2.53 34,102
2010-03-01 Gorman Kevin Charles (President and CEO) Sale 15,609 2.53 39,490
2010-03-01 Valeur Jensen Margaret E (EVP and General Counsel) Sale 12,490 2.53 31,599
2010-01-12 Coughlin Timothy P (VP and Chief Financial Officer) Sale 8,697 2.52 21,951
2010-01-12 Gorman Kevin Charles (President and CEO) Sale 9,445 2.52 23,829
2010-01-12 Valeur Jensen Margaret E (EVP and General Counsel) Sale 8,697 2.52 21,942
2010-01-04 Grigoriadis Dimitri E. (Vice President, Research) Sale 1,503 2.67 4,016
2010-01-04 Bozigian Haig P. (Sr Vice President, Development) Sale 751 2.64 1,982
2010-01-04 Obrien Christopher Flint (Sr. VP & Chief Medical Officer) Sale 1,503 2.65 3,982
2009-11-05 Mitchell W Thomas (Director) Buy 900 2.17 1,953
2009-09-28 Grigoriadis Dimitri E. (Vice President, Research) Sale 3,038 3.12 9,463
2009-09-28 Bozigian Haig P. (Sr Vice President, Development) Sale 3,642 3.11 11,337
2009-09-28 Obrien Christopher Flint (Sr. VP & Chief Medical Officer) Sale 4,859 3.11 15,130
2009-03-30 Grigoriadis Dimitri E. (Vice President, Research) Sale 12,606 3.43 43,225
2009-03-30 Bozigian Haig P. (Sr Vice President, Development) Sale 12,774 3.43 43,776
2009-03-30 Coughlin Timothy P (VP and Chief Financial Officer) Sale 12,117 3.43 41,537
2009-03-30 Obrien Christopher Flint (Sr. VP & Chief Medical Officer) Sale 12,151 3.43 41,653
2009-03-30 Gorman Kevin Charles (President and CEO) Sale 15,146 3.43 51,920
2009-03-30 Valeur Jensen Margaret E (EVP and General Counsel) Sale 12,117 3.43 41,549
2009-01-23 Bvf Inc/il (Other) Buy 9,000 3.10 27,873
2009-01-22 Bvf Inc/il (Other) Buy 6,900 3.10 21,390
2009-01-21 Bvf Inc/il (Other) Buy 25,200 3.06 77,086
2009-01-20 Bvf Inc/il (Other) Buy 75,000 3.08 231,075
2009-01-15 Bvf Inc/il (Other) Buy 7,400 3.05 22,584
2009-01-13 Coughlin Timothy P (VP and Chief Financial Officer) Sale 8,463 3.38 28,647
2009-01-13 Gorman Kevin Charles (President & CEO) Sale 9,195 3.37 31,005
2009-01-12 Valeur Jensen Margaret E (EVP and General Counsel) Sale 8,463 3.25 27,487
2009-01-05 Grigoriadis Dimitri E. (Vice President, Research) Sale 1,462 3.40 4,975
2009-01-05 Bozigian Haig P. (Sr Vice President, Development) Sale 733 3.40 2,488
2009-01-05 Obrien Christopher Flint (Sr. VP & Chief Medical Officer) Sale 1,462 3.41 4,991
2008-12-30 Bvf Inc/il (Other) Buy 10,600 2.80 29,679
2008-12-01 Bvf Inc/il (Other) Buy 99,400 2.35 233,093
2008-11-24 Bvf Inc/il (Other) Buy 54,400 2.45 133,225
2008-10-10 Bvf Inc/il (Other) Buy 447,047 2.72 1,215,967
2008-09-29 Grigoriadis Dimitri E. (Vice President, Research) Sale 3,017 4.71 14,194
2008-09-29 Bozigian Haig P. (Sr Vice President, Development) Sale 3,618 4.70 16,986
2008-09-29 Obrien Christopher Flint (Sr. VP & Chief Medical Officer) Sale 4,824 4.69 22,624
2008-07-08 Bvf Inc/il (Other) Buy 3,400 4.25 14,450
2008-07-07 Bvf Inc/il (Other) Buy 115,700 4.24 490,683
2008-07-03 Bvf Inc/il (Other) Buy 11,100 4.15 46,031
2008-07-02 Bvf Inc/il (Other) Buy 26,600 4.18 111,081
2008-05-28 Bvf Inc/il (Other) Buy 22,100 4.72 104,312
2008-05-27 Bvf Inc/il (Other) Buy 5,000 4.71 23,555
2008-05-16 Bvf Inc/il (Other) Buy 26,300 4.65 122,347
2008-05-15 Bvf Inc/il (Other) Buy 126,300 4.63 584,390
2008-05-13 Grigoriadis Dimitri E. (Vice President, Research) Sale 6,485 5.05 32,749
2008-03-20 Bvf Inc/il (Other) Buy 43,600 5.00 218,000
2008-03-18 Bvf Inc/il (Other) Buy 153,000 4.96 759,033
2008-03-12 Bvf Inc/il (Other) Buy 14,800 5.00 74,000
2008-03-11 Bvf Inc/il (Other) Buy 141,800 4.90 694,252
2008-03-10 Bvf Inc/il (Other) Buy 225,000 4.89 1,100,475
2008-03-07 Bvf Inc/il (Other) Buy 104,600 4.99 521,849
2008-03-06 Bvf Inc/il (Other) Buy 86,700 5.00 433,153
2008-03-04 Bvf Inc/il (Other) Buy 23,200 4.97 115,396
2008-03-03 Bvf Inc/il (Other) Buy 98,000 4.93 482,944
2008-02-29 Bvf Inc/il (Other) Buy 47,400 4.99 236,668
2008-02-28 Bvf Inc/il (Other) Buy 23,000 5.00 115,000
2008-02-26 Bvf Inc/il (Other) Buy 20,800 5.00 103,958
2008-02-25 Bvf Inc/il (Other) Buy 108,000 4.96 535,140
2008-02-22 Bvf Inc/il (Other) Buy 79,000 4.84 382,281
2008-02-21 Bvf Inc/il (Other) Buy 106,000 4.70 498,518
2008-02-12 Coughlin Timothy P (VP and Chief Financial Officer) Sale 7,857 5.03 39,520
2008-02-12 Ranieri Richard J (Sr. VP, Human Resources) Sale 9,666 5.04 48,697
2008-02-12 Gorman Kevin Charles (President & CEO) Sale 8,230 5.03 41,372
2008-02-12 Valeur Jensen Margaret E (EVP and General Counsel) Sale 7,663 5.03 38,560
2008-02-05 Grigoriadis Dimitri E. (Vice President, Research) Sale 1,206 5.30 6,397
2008-02-05 Bozigian Haig P. (Sr Vice President, Development) Sale 722 5.30 3,830
2007-04-23 Lyons Gary A (President and CEO) Option Ex 63,091 7.38 465,296
2006-05-17 Hawran Paul W (Executive VP and CFO) Sale 115,481 19.98 2,306,963
2006-03-03 Vale Wylie W (Director) Sale 10,000 70.01 700,130
2005-12-21 Vale Wylie W (Director) Sale 10,000 65.03 650,300
2005-12-08 Gorman Kevin Charles (Sr VP, Business Dev.) Sale 3,000 62.85 188,547
2005-12-05 Lyons Gary A (President and CEO) Sale 5,000 61.94 309,700
2005-11-22 Lyons Gary A (President and CEO) Sale 5,000 61.77 308,840
2005-11-18 Vale Wylie W (Director) Sale 10,000 60.04 600,410
2005-11-18 Lyons Gary A (President and CEO) Sale 5,000 59.71 298,550
2005-11-03 Lyons Gary A (President and CEO) Sale 10,000 55.64 556,370
2005-11-02 Vale Wylie W (Director) Sale 5,021 55.00 276,155
2005-11-01 Vale Wylie W (Director) Sale 4,979 55.01 273,894
2005-10-28 Lyons Gary A (President and CEO) Sale 10,000 51.50 515,000
2005-09-07 Vale Wylie W (Director) Sale 10,000 50.00 500,000
2005-09-07 Lyons Gary A (President and CEO) Sale 10,000 49.00 490,000
2005-08-18 Lyons Gary A (President and CEO) Sale 5,000 46.75 233,750
2005-06-15 Lyons Gary A (President and CEO) Sale 5,000 39.70 198,500
 1   2 

Insider trading activities including stock purchases, stock sales, and option exercises of NBIX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Neurocrine Biosciences Inc (symbol NBIX, CIK number 914475) see the Securities and Exchange Commission (SEC) website.